Evolve’s Dr. Steven Frese to speak at the Human Microbiome Congress, Jan 24-25

By January 23, 2017News

Davis, California Jan 23, 2016 – Evolve BioSystems, Inc., a mid-stage microbiome company developing novel solutions for gut dysbiosis, is pleased to announce that Dr. Steven Frese, head of R&D, will be presenting at the North American Human Microbiome Congress, January 24-25 in San Diego.

The conference serves as a learning and networking platform for microbiologists, clinicians regulatory and industry executives in the microbiome space. Dr. Frese will be presenting Evolve’s current research on dysbiosis in the infant gut, resulting from pre-term birth, Caesarian-section deliveries, and exclusive use of infant formula.

For more details on the North American Human Microbiome Congress, visit: http://humanmicrobiomecongress.com/

To learn more about Evolve BioSystems, visit: www.evolvebiosystems.com

Evolve Contact:
Tracy Shafizadeh, PhD
Director, Scientific Communications
tshafizadeh@evolvebiosystems.com

About Evolve BioSystems

Evolve BioSystems, Inc. is a privately-held microbiome company dedicated to developing the next generation of products to establish, restore, and maintain a healthy human gut microbiome. Evolve is a spin-out from the Foods for Health Institute (FFHI) at the University of California, Davis and builds on more than a decade of research into understanding the unique partnership of the infant gut microbiome and breast milk components. Having led to the discovery and development of products to resolve infant gut dysbiosis, Evolve’s discovery platform is now being applied to solving gut dysbiosis throughout the human life cycle as well as in various animal species. Evolve completed a $9 million Series A capital raise in 2015 and has now successfully completed a milestone proof-of-concept study to demonstrate the efficacy of its initial proprietary offering.  In addition, Evolve is undertaking further clinical studies to build out its offering of microbiome-based solutions across a spectrum of unmet clinical needs.

Leave a Reply